News & Updates
NRTX-1001 investigational treatment has been well tolerated in all initial subjects Positive decision from data safety monitoring board (DSMB) on review of first cohort safety data greenlights dosing of five additional subjects in the second, highest dose, cohort First two subjects continue to report a >95% reduction in overall average monthly seizure counts one year…
Read More
Excerpt from the Press Release: Bioxodes SA has received €12 million ($13M) in a Series A funding from historic investors. This financial backing includes €8.6 million ($9.3M) in capital and €3.4 million ($3.7M) in non-dilutive funding from the Wallonia region. It comes on top of the €27 million ($29.2M) in capital and subsidies previously raised by Bioxodes, bringing to €39 million ($42.2M)…
Read More
Excerpt from the Press Release: The trial met its primary endpoint of progression-free survival (PFS) and showed that belantamab mafodotin when combined with bortezomib plus dexamethasone (BorDex) significantly extended the time to disease progression or death versus daratumumab plus BorDex, an existing standard of care for relapsed/refractory multiple myeloma. A strong and clinically meaningful overall…
Read More
Excerpt from the Press Release: Inhalable medicines are already widely used to treat conditions such as asthma, epilepsy, allergies and Parkinson’s but, to date, delivery options have been limited due to user accessibility, cost, performance and impact on the environment. 1nhaler has developed a way of enabling many different dry powder drugs to be readily…
Read More
Excerpt from the Press Release: NeuroOne Medical Technologies Corporation have announced that the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application 16/812,702, titled “Agent-Delivering Neural Probe Devices and Related Systems and Methods,” which covers novel electrodes that can operate as a standard neural electrode that also delivers a treatment agent to…
Read More
Excerpt from the Press Release: “This expansion places BIOVECTRA at the forefront of supporting the next generation of treatments for today’s rare and incurable diseases and producing vaccines to tackle future pandemics,” said BIOVECTRA CEO Oliver Technow. “Today also marks a milestone in the accelerated growth of Atlantic Canada’s bioscience sector and celebrates the creation…
Read More
Phase 1 single ascending and multiple ascending dose studies previously completed demonstrate safety, tolerability and dosing to reach optimal target engagement Excerpt from the Press Release: SAN FRANCISCO, Nov. 16, 2023 /PRNewswire/ — Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of Alzheimer’s and other diseases of aging, today announced clearance by…
Read More
Results demonstrate KarXT was not associated with clinically meaningful increases in blood pressure in adults with schizophrenia KarXT demonstrated a mean change from baseline to week 8 in 24-hour ambulatory systolic blood pressure of -0.59 mmHg, the primary endpoint in the trial KarXT was generally well tolerated, with a side effect profile consistent with prior…
Read More
Excerpt from the Press Release: HAMILTON, ON and BOSTON, Nov. 16, 2023 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT), today announced that the companies have entered into a new agreement for the supply of generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials. Under…
Read More
Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced that researchers will present data from an ongoing phase 2 trial study of BPGbio lead candidate, BPM31510, in patients with newly diagnosed glioblastoma multiforme (GBM), at the Society for Neuro-Oncology Annual Meeting…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?